Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 13;27(10):110941.
doi: 10.1016/j.isci.2024.110941. eCollection 2024 Oct 18.

Exploring temporal and sex-linked dysregulation in Alzheimer disease phosphoproteome

Affiliations

Exploring temporal and sex-linked dysregulation in Alzheimer disease phosphoproteome

Serhan Yılmaz et al. iScience. .

Abstract

This study aims to characterize dysregulation of phosphorylation for the 5XFAD mouse model of Alzheimer disease (AD). Employing global phosphoproteome measurements, we analyze temporal (3, 6, and 9 months) and sex-dependent effects on mouse hippocampus tissue to unveil molecular signatures associated with AD initiation and progression. Our findings reveal consistent phosphorylation of known AD biomarkers APOE and GFAP in 5XFAD mice, alongside candidates BIG3, CLCN6, and STX7, suggesting their potential as biomarkers for AD pathology. In addition, we identify PDK1 as a significantly dysregulated kinase at 9 months in females, and the regulation of gap junction activity as a key pathway associated with Alzheimer disease across all time points. AD-Xplorer, the interactive browser of our dataset, enables exploration of AD-related changes in phosphorylation, protein expression, kinase activities, and pathways. AD-Xplorer aids in biomarker discovery and therapeutic target identification, emphasizing temporal and sex-specific nature of significant phosphoproteomic signatures. Available at: https://yilmazs.shinyapps.io/ADXplorer.

Keywords: Neuroscience; cell biology; molecular biology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Phosphosites identified as differentially phosphorylated for Alzheimer disease 5XFAD model at different time points (A–C) Volcano plots indicating the screened phosphosites with high or low phosphorylation at 3-/6-/9-month time points. The dashed horizontal lines in each plot indicate the statistical significance threshold (p < 0.1 and FDR ≤ 0.1) and the vertical line the threshold on fold changes (>2). The statistically significant phosphosites at FDR ≤ 0.1 level are marked as stars (∗). The top differentially expressed phosphosites are highlighted in each panel. (D) Venn diagram showing the number of phosphosites that pass the screening (p ≤ 0.1 and 0.5 ≥ FC ≥ 2) for 3/6/9 months data. Whereas, the numbers in parentheses indicate the significant ones at FDR ≤ 0.1 level. (E and F) Identified phosphosites that pass the screening in sex-specific analysis. The y axis indicates a lower-bound of the 95% confidence intervals for each phosphosite.
Figure 2
Figure 2
Proteins identified as differentially phosphorylated for Alzheimer disease 5XFAD model across different time points (Left) The bars indicate the mean phosphorylation for each protein identified as consistently phosphorylated, and the error bars indicate 95% confidence intervals. Proteins are marked according to their statistical significance levels: ∗p ≤ 0.1, ∗∗FDR ≤ 0.1, and ∗∗∗FDR ≤ 0.01.
Figure 3
Figure 3
Inferred kinase activities across 3-/6-/9-month time points and different sexes For each subplot, the top seven most significant kinases are shown. The error bars indicate 95% confidence intervals. Kinases are marked according to their statistical significance levels: ∗p ≤ 0.1, ∗∗FDR ≤ 0.1, and ∗∗∗FDR ≤ 0.01.
Figure 4
Figure 4
Dysregulation of PDK1 at protein expression and phosphorylation level for different sexes and time points of Alzheimer disease 5XFAD model (A) Protein expression (log2-FC) of PDK1 for all time points and sexes. (B) The auto-phosphorylation (log2-FC) of PDK1 for all time points and sexes. (C) Inferred activity score of PDK1 for all time points and sexes. (D) Phosphorylation (log2-FC) of known targets of PDK1 for 9 months’ data. For all plots, the coloring is done to reflect the degree of statistical significance based on Z scores.
Figure 5
Figure 5
Validation data results for candidate proteins Proteins are marked according to their statistical significance levels: ∗p ≤ 0.1, ∗∗FDR ≤ 0.1, and ∗∗∗FDR ≤ 0.01.

Update of

Similar articles

Cited by

References

    1. GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016 a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106. doi: 10.1016/S1474-4422(18)30403-4. - DOI - PMC - PubMed
    1. Ferreira D., Wahlund L.-O., Westman E. The heterogeneity within Alzheimer's disease. Aging (Albany NY) 2018;10:3058–3060. doi: 10.18632/aging.101638. - DOI - PMC - PubMed
    1. Van der Flier W.M. Clinical heterogeneity in familial Alzheimer's disease. Lancet Neurol. 2016;15:1296–1298. doi: 10.1016/S1474-4422(16)30275-7. - DOI - PubMed
    1. Devi G., Scheltens P. Heterogeneity of Alzheimer’s disease: consequence for drug trials? Alzheimers Res. Ther. 2018;10:122. doi: 10.1186/s13195-018-0455-y. - DOI - PMC - PubMed
    1. Troncoso J.C., Martin L.J., Dal Forno G., Kawas C.H. Neuropathology in controls and demented subjects from the Baltimore longitudinal study of aging. Neurobiol. Aging. 1996;17:365–371. doi: 10.1016/0197-4580(96)00028-0. - DOI - PubMed

LinkOut - more resources